← Back to Clinical Trials
Recruiting NCT02095808

NCT02095808 Metabolic Biomarkers in Thoracic Cancers

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02095808
Status Recruiting
Phase
Sponsor University of Texas Southwestern Medical Center
Condition Lung Cancer
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2013-03-20
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Imaging Biomarkers

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2013-03-20 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this research study is to develop a method of using magnetic resonance imaging (MRI) to evaluate lung tumors and other thoracic malignancies. An MRI is a scanning device that uses magnets to make images (pictures) of the body. This study is being done to determine what series of reactions (metabolic pathways) pulmonary nodules use as they burn sugar as fuel for growth. The manner in which the tumor burns (metabolizes) sugar for fuel is being investigated by using a natural, slightly modified, sugar solution (13C-glucose) and studying a small sample of the tumor once it is removed at the time of surgery.

Eligibility Criteria

Inclusion Criteria: 1. Patients must have known or probable malignant lesions requiring surgical biopsy or excision. 2. Subjects of all races and ethnic origins over 18 years of age. Exclusion Criteria: 1. Not a surgical candidate. 2. Poorly controlled diabetes.

Contact & Investigator

Central Contact

Ebele Mbanugo, Ed.D, CCRP

✉ ebele.mbanugo@utsouthwestern.edu

📞 214-648-7097

Principal Investigator

Kemp H Kernstine, MD

PRINCIPAL INVESTIGATOR

University of Texas Southwestern Medical Center

Frequently Asked Questions

Who can join the NCT02095808 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02095808 currently recruiting?

Yes, NCT02095808 is actively recruiting participants. Contact the research team at ebele.mbanugo@utsouthwestern.edu for enrollment information.

Where is the NCT02095808 trial being conducted?

This trial is being conducted at Dallas, United States.

Who is sponsoring the NCT02095808 clinical trial?

NCT02095808 is sponsored by University of Texas Southwestern Medical Center. The principal investigator is Kemp H Kernstine, MD at University of Texas Southwestern Medical Center. The trial plans to enroll 200 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology